

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of March 2018

	31.03.2018	31.12.2017
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	26 268	26 803
Intangible assets	3 067	2 998
Investment in minority interest	1	1
Trade receivables	5 960	5 960
Total non-current assets	35 296	35 762
Current assets		
Inventories	4 849	5 190
Trade and other receivables	60 866	55 998
Treasury shares redeemed	11	8
Cash and cash equivalents	28	24
Total current assets	65 754	61 220
Total assets	101 050	96 982
LIABILITIES		
Equity		
Share capital	64 300	64 300
Reserves	9 172	9 172
Retained earnings	11 854	8 831
Total	85 326	82 303
Non-current liabilities		
Long-term loans	521	590
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	83	83
Total non-current liabilities	1 912	1 981
Current liabilities		
Trade and other liabilities	3 007	2 134
Short-term loans	9 778	9 784
Current portion of long-term loans	434	491
Current corporate income tax		78
Other tax liabilities	593	211
Total current liabilities	13 812	12 698
Total liabilities	15 724	14 679
Total equity and liabilities	101 050	96 982

Date of preparation: 23.04.2018

Sofia

Prepared by:.....

/ P. Moneya /

Executive Director:.....

/B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of March 2018

	31.03.2018	31.03.2017
	BGN'000	BGN'000
Revenue	9 164	7 644
Other income		
Total income	9 164	7 644
Carrying amount of goods sold	(534)	(164)
Changes in inventories of finished products and work in progress	124	374
Materials and services	(3 585)	(3 051)
Personnel expenses	(870)	(782)
Depreciation / amortisation expenses	(879)	(729)
Other expenses	(82)	(26)
Finance income	5	7
Finance costs	(74)	(100)
Total expenses	(5 895)	(4 471)
Profit before taxation	3 269	3 173
Corporate income tax expense	(246)	(317)
Profit/Loss for the period	3 023	2 856
 Total comprehensive income for the period		
Earnings per share / in BGN per 1 share /	0.05	0.05

Date of preparation: 23.04.2018


Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of March 2018

	31.03.2018	31.03.2017
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	6 463	7 873
Payments to suppliers of materials, goods and services	(2 906)	(3 222)
Payments to personnel	(795)	(709)
Payments of interest and dividends	(2)	(3)
Corporate income tax payments	(325)	(301)
Other proceeds / payments	(1 654)	(1 342)
Net cash flows	781	2 296
Cash flows from investing activities		
Payments on non-current assets acquired	(588)	(824)
Net cash flows	(588)	(824)
Cash flows from financial activities		
Proceeds from loans		
Payments on loans		(1 174)
Payment of interest, dividends	(49)	(68)
Payments on finance lease	(137)	(240)
Other proceeds/payments	(3)	
Net cash flows	(189)	(1 482)
Change in cash and cash equivalents	4	(10)
Cash and cash equivalents at the beginning of the period	24	50
Cash and cash equivalents at the end of the period	28	40

Date of preparation: 23.04.2018

Sofia

Prepared by:.....

/ P. Moneva /

Executive

Director:.....

/B. Georgiev /



Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of March 2018

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2017	56 600	3 149	4 661	8 585	72 995
Profit/loss for the period				8 831	8 831
Other comprehensive income		477			477
Including from tax effect of the revaluation of property, plant and equipment		(60)			(60)
Total comprehensive income		477		8 831	9 308
Issue of shares by the owners	7 700			(7 700)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			885	(885)	
Total amount of income and expenses recognised during the period	7 700		885	(8 585)	
Balance as of 31.12.2017	64 300	3 626	5 546	8 831	82 303
Balance as of 01.01.2018	63 400	3 626	5 546	8 831	82 303
Profit/loss for the period				3 023	3 023
Other comprehensive income					
Total comprehensive income				3 023	3 023
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.03.2018	63 400	3 626	5 546	11 854	85 326

Date of preparation: 23.04.2018
Sofia

Prepared by:.....
/P. Moneva/

Executive Director:.....
/B. Georgiev /

